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Rho-associated kinase 2 (Rock2) is known to promote tumorigenesis in hepatocellular carcinoma
(HCC). CCAAT/enhancer-binding protein delta (CEBPD) functions as a tumor suppressor. In this
study, we found that the expression of Rock2 and CEBPD are inversely correlated. Knockdown of
Rock2 increased CEBPD expression and inhibited the proliferation of HCC cells in vitro and
in vivo. Mechanistically, we found that Rock2 regulates CEBPD expression through the p-GSK3b/b-
catenin pathway. Taken together, we identiﬁed a novel Rock2–p-GSK3b/b-catenin–CEBPD regulatory
circuitry, the dysfunction of which may contribute to the tumorigenic characteristic of HCC.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Surgical resection is the primary method for treating hep-
atocellular carcinoma (HCC) but less than 20% of patients receive
timely radical surgical resection, which is mainly due to high
degrees of malignancy, early metastasis, and the rapid inﬁltrativegrowth of HCC cells [1–3]. Therefore, studying the molecular reg-
ulatory mechanisms underlying HCC proliferation and identifying
an effective prevention and treatment target are key topics in
HCC treatment research.
Rho-associated coiled-coil forming protein kinase 2 (Rock2) is a
key signaling molecule in the Rho/Rock signal transduction path-
way that can regulate the expression of downstream genes by
regulating the activity or phosphorylation levels of its target pro-
teins [4–6]. An increasing number of studies have focused on
Rock2 in malignant tumors. These previous reports have shown
that increased Rock2 expression is correlated with the occurrence
and development of tumors in many human cancers, including
HCC, breast cancer and lung cancer [4,7,8]. Recently emerging evi-
dence links the biological function of Rock2 to HCC carcinogenesis
and progression. High levels of Rock2 expression can promote the
invasion and metastasis of HCC and are associated with poor prog-
nosis [9]. Our previous study also conﬁrmed that Rock2
overexpression in HCC promotes the invasion and migration of
HCC and that the downregulation of Rock2 can inhibit the pro-
liferation of HCC cells [10,11].
The CCAAT enhancer-binding protein C/EBPd (CEBPD) belongs
to the family of CCAAT enhancer binding proteins and participates
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studies have reported that CEBPD is a tumor suppressor gene and
plays an important role in the tumor proliferation processes. For
example, the downregulation of CEBPD can promote cell prolifera-
tion in breast cancer, whereas increased CEBPD expression inhibits
prostate cancer proliferation [13,14]. However, the expression and
regulatory mechanisms of CEBPD in HCC are not yet clear. Because
HCC is a tumor with strong proliferative abilities, we speculated
that Rock2 can affect HCC proliferation through the regulation of
CEBPD expression.
In this study, we ﬁrst found that Rock2 expression is upregu-
lated and that CEBPD is downregulated in HCC tissues, and the
levels exhibited a negative correlation. In addition, the in vitro
and in vivo studies provided evidence that CEBPD expression
induced by Rock2 silencing can inhibit the proliferation of HCC.
Further investigations indicated that Rock2 regulated CEBPD
through the p-GSK3b/b-catenin signaling pathway.
2. Materials and methods
2.1. Specimens
Human HCC tissues were collected from 51 patients who under-
went HCC resection at the Second Afﬁliated Hospital of Nanchang
University between January 2010 and June 2013. The healthy liver
tissues were surgically obtained from 2 hepatic hemangioma
patients. Informed consent was obtained from each patient, and
the study protocol was approved by the Ethics Committee of the
Second Afﬁliated Hospital of Nanchang University.
2.2. Cell culture, plasmids and reagents
The human HCC cell lines HCCLM3, SMMC7721, HepG2,
MHCC97H, Hep3B and Huh-7 were purchased from the Shanghai
Institute of Cell Biology, China. The immortalized liver cell line
HL-7702 was obtained from Shanghai Fu Xiang Biotechnology
Co., Ltd., China. The cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) (Gibco, Grand Island, NY, USA) supple-
mented with fetal bovine serum (Hyclone, Logan, UT, USA) to a
ﬁnal concentration of 10% and antibiotics at 37 C with 5% CO2.
The plasmids and reagents used in this study are provided in
Supplementary materials and methods.
2.3. Real-time quantitative polymerase chain reaction (qRT-PCR),
Western blotting analysis, and co-immunoprecipitation (Co-IP)
The qRT-PCR, Western blotting, and Co-IP assays were per-
formed as previously described [15]. The speciﬁc primers used
for PCR ampliﬁcation are shown in Supplementary Table S1.
Experiments were performed intriplicate.
2.4. Cell counting kit-8 (CCK-8) assay
After transfection, the cells were seeded in a 96-well plate at a
density of 1  104 cells per well and incubated for 4 days. The
in vitro cell proliferation was evaluated using a CCK-8 (Beyotime
Institute of Biotechnology, China) according to the manufacturer’s
instructions. After incubation for 2 h at 37 C, the absorbance was
measured at 450 nm using a microplate reader iMark (Bio-Rad).
Experiments were performed in triplicate.
2.5. EdU assay
Cell proliferation was measured by the 5-ethynyl-20-deoxyuri-
dine (EdU) assay using an EdU assay kit (Ribobio, Guangzhou,
China) according to the manufacturer’s instructions. HCC cellswere cultured in triplicate at a density of 5  105 cells per well in
12-well plates for 48 h. The cells were then exposed to 50 lM
EdU for 2 h at 37 C, ﬁxed with 4% formaldehyde for 30 min at
room temperature and treated with 0.5% Triton X-100 for 20 min
at room temperature for permeabilization. After three washes with
PBS, the cells were treated with 300 lL of 1 ApolloR reaction
cocktail for 30 min. Subsequently, the DNA contents of the
cells in each well were stained with 100 lL of Hoechst 33342
(5 lg/mL) for 30 min and visualized under a ﬂuorescence micro-
scope. Experiments were performed in triplicate.
2.6. Luciferase reporter gene assay
The cells were seeded at a density of 1  105 cells per well in
six-well plates and incubated for 24 h before transfection with
the TCF4 promoter luciferase plasmid (2 mg) or the CEBPD
promoter luciferase plasmid (2 mg) using Lipofectamine™ LTX
according to the manufacturer’s instructions. The cells were
co-transfected with 50 ng of the pRLTK plasmid for normalization.
After 48 h, the luciferase activity was measured using dual-
luciferase assay kit (Promega, Madison, WI, USA). The ﬁreﬂy
luciferase activity was expressed as relative light units (RLUs)
compared with the Renilla luciferase activity. All of the assays were
performed in triplicate.
2.7. Tumorigenicity assay
For in vivo tumorigenicity assays, 1  106 cells in 100 lL of phos-
phate-buffered saline were injected subcutaneously into the ﬂanks
of nudemice (Shanghai SLAC Laboratory Animal Co., Ltd.). The tumor
size was measured using a caliper (calculated volume = shortest
diameter2  longest diameter/2) at ﬁve-day intervals. After 40 days,
photographs were taken, the mice were anesthetized, and the
tumors were harvested and individually weighed. The data are pre-
sented as the tumor weight (means ± S.D.). The animal work was
approved by the Ethics Committee for Animal Experiments of the
Second Afﬁliated Hospital of Nanchang University.
2.8. Statistical analysis
All of the datawere analyzed using SPSS 16.0 (SPSS, Inc., Chicago,
IL, USA). The results are presented as the means ± S.D. from three
independent experiments. The differences between the groups
were analyzed by Student’s t test when two groups were compared
or by one-way ANOVAwhenmore than two groupswere compared.
The test results were considered signiﬁcant at P < 0.05.
3. Results
3.1. Expression levels of Rock2 and CEBPD are inversely correlated in
HCC tissues
To investigate the correlation between the expression levels of
Rock2 and CEBPD in HCCs, we ﬁrst determined the expression
levels of Rock2 and CEBPD in 51 pairs of HCC and adjacent tissues.
The qRT-PCR results revealed that the average fold change of Rock2
mRNA expression was signiﬁcantly increased and that the CEBPD
mRNA expression was signiﬁcantly decreased in HCC tissues
(Fig. 1A). Additionally, the Western blotting results showed that
Rock2 protein was overexpressed in 62.74% (32/51) of the HCC tis-
sue samples. In contrast, the CEBPD protein was downregulated in
60.78% (31/51) of the HCC tissues (Fig. 1B and C). We also observed
low expression of Rock2 and high expression of CEBPD in healthy
adult liver (Fig. S3). Moreover, the scatter plots showed that the
Rock2 and CEBPD mRNA and protein expression levels were inver-
sely correlated in HCC tissues (Fig. 1D).
Fig. 1. Rock2 overexpression is inversely correlated with CEBPD expression in human HCC. (A) Quantiﬁcation of Rock2 and CEBPD mRNA expression levels in 51 HCC tumors
and peritumoral liver tissues (⁄P < 0.05, ⁄⁄⁄P < 0.001, as determined by paired Student’s t-test). (B) Representative Western blotting analysis of Rock2 and CEBPD protein
expression (T: tumor, NT: non-tumorous tissues). (C) Quantiﬁcation of Rock2 and CEBPD protein expression levels in 51 paired HCC and adjacent non-tumoral livers through
Western blotting. The protein expression level of tubulin was used as an internal control (⁄P < 0.05, ⁄⁄⁄P < 0.001). (D) Scatter plots show an inverse correlation between Rock2
and CEBPD mRNA and protein levels in 51 HCCs (r = 0.2853, P < 0.05 and r = 0.3091, P < 0.05).
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represses HCC proliferation in vitro and in vivo
To investigate whether Rock2 regulates CEBPD expression in
HCC cells, we ﬁrst detected the expression levels of Rock2 and
CEBPD in various HCC cells by qRT-PCR and Western blotting.
The results showed that the Rock2 expression levels were
negatively correlated with the levels of CEBPD (Fig. 2A). We thenmanipulated the Rock2 levels by stably transfected Rock2 shRNA
or Rock inhibitor (Y27632) and found that the downregulation of
Rock2 can increase the CEBPD mRNA and protein expression
levels in HCCLM3 and SMMC7721 cells (Fig. 2B and C). The
CEBPD promoter activity was also increased (Fig. 2D). Further-
more, the cell proliferation ability was signiﬁcantly decreased in
the shRock2 or Rock inhibitor group (Fig. 2E and F). In addition,
the in vivo experiment further conﬁrmed that the tumors formed
Fig. 2. Stable knockdown of Rock2 increases CEBPD expression and suppresses HCC cell proliferation in vitro and in vivo. (A) qRT-PCR andWestern blot analyses of Rock2 and
CEBPD expression in human normal hepatocytes and HCC cell lines. (B and C) qRT-PCR and Western blot analyses were performed to detect the Rock2 and CEBPD expression
levels in HCCLM3 and SMMC7721 cells stably transfected with the shNC vector or the shRock2 plasmid or treated with a Rock inhibitor (Y27632) (⁄⁄P < 0.01, ⁄⁄⁄P < 0.001). (D)
Luciferase analysis for CEBPD promoter activity in Rock2-knockdown or Y27632-treated HCCLM3 and SMMC7721 cells (⁄P < 0.05, ⁄⁄⁄P < 0.001). (E) CCK-8 assays. Stable
Rock2-knockdown or Y27632-treated cells showed lower cell proliferation compared with the shNC control groups. (F) EdU cell proliferation assays of HCCLM3 and
SMMC7721 cells inhibiting Rock2. Data were drawn from three independent experiments, (⁄⁄⁄P < 0.001). (G and H) The in vivo tumor formation was examined by
subcutaneously injecting SMMC7721-shNC or SMMC7721-shRock2 cells into the ﬂank of nude mice. Representative photographs and tumor weight obtained 40 days after
inoculation (⁄P < 0.05, ⁄⁄⁄P < 0.001, as determined by Student’s t-test). (I) The tumor sizes of the SMMC7721-shNC and SMMC7721-shRock2 groups of nude mice were
measured, and corresponding tumor growth curves were obtained (⁄P < 0.05).
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Fig. 3. CEBPD is essential for Rock2-mediated HCC proliferation. (A) The protein levels of Rock2 and CEBPD were detected by Western blot analysis. The knockdown of CEBPD
expression markedly inhibited the increase in CEBPD expression observed in HCCLM3- and SMMC7721-shRock2 cells. (B and C) CCK-8 assays and EdU cell proliferation assays
showed that CEBPD inhibition rescued the decreased cell proliferation ability of HCCLM3- or SMMC7721-shRock2 cells (⁄⁄P < 0.01). (D) Western blotting was used to detect
the expression of Rock2 and CEBPD. The overexpression of ectopic CEBPD attenuated the loss of CEBPD expression in Huh-7- and HepG2-Rock2 cells. (E-F) CCK-8 assays and
EdU cell proliferation assays showed that the overexpression of ectopic CEBPD signiﬁcantly reduced the Rock2-enhanced cell proliferation observed in Huh-7-Rock2 and
HepG2-Rock2 cells. Data were drawn from three independent experiments. (⁄⁄P < 0.01).
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and weight compared with the tumors formed by the control cells
(Fig. 2G–I). These results indicate that the stable knockdown of
Rock2 can increase CEBPD expression and inhibit HCC cell pro-
liferation in vitro and in vivo.
3.3. CEBPD is critical for Rock2-mediated HCC cell proliferation
To further validate that Rock2 mediates HCC proliferation by
regulating CEBPD, we ﬁrst inhibited the expression of CEBPD in
Rock2-knockdown HCC cells and then observed the Rock2 and
CEBPD protein expression levels and cell proliferation abilities.
The Western blot analysis results showed that the downregulation
of CEBPD markedly inhibited the increase of CEBPD expression in
Rock2-knockdown HCCLM3 and SMMC7721 cells (Fig. 3A).
Simultaneously, the downregulation of CEBPD can rescue the
decreased proliferation abilities induced by Rock2 knockdown
(Fig. 3B and C). In contrast, the overexpression of ectopic CEBPD
attenuated the loss of CEBPD expression and signiﬁcantly reduced
cell proliferation in Rock2-overexpressing Huh-7 and HepG2 cells(Fig. 3D–F). Thus, these results conﬁrm that Rock2 promotes HCC
proliferation at least in part by down regulating CEBPD expression.
3.4. Rock2 regulates CEBPD expression through the p-GSK3b/b-catenin
pathway in HCC cells
To clarify the mechanism through which Rock2 regulates CEBPD
in HCC cells, we found no direct interaction between Rock2 and
CEBPD proteins in HCC cells (Fig. 4A). In addition, it has been
reported that Rock2 can regulate its substrate protein by affecting
the phosphorylation of Gsk-3b [16]. Therefore, we speculated that
Rock2 regulated CEBPD-mediated HCC proliferation via the pGSK-
3b pathway. The results showed that the knockdown of Rock2 can
signiﬁcantly decrease the phosphorylation of GSK3b at serine 9 and
increased CEBPD protein expression and promoter activity in
HCCLM3 and SMMC7721 cells, but the level of total GSK3b was
not changed (Fig. 4B and C). In contrary, the overexpression of
ectopic Rock2 expression in Huh-7 and HepG2 cells may increase
the phosphorylation of GSK3b at serine 9 and decreased CEBPD
protein expression and promoter activity (Fig. 4B and C). Further
Fig. 4. Rock2 regulates CEBPD expression through p-GSK3b/b-catenin. (A) Endogenous Rock2 and CEBPD were not directly bound. (B). Western blot analysis was used to
measure the expression levels of Rock2, p-GSK3b, total GSK3b, and CEBPD in Rock2-silenced and Rock2-overexpressing HCC cells. (C) Luciferase analysis for CEBPD promoter
activity in Rock2-silenced and Rock2-overexpressing HCC cells (⁄⁄P < 0.01). (D) Western blotting analysis was used to measure the expression of Rock2, p-GSK3b, total GSK3b
and CEBPD in Rock2-overexpressing Huh-7 cells treated with CHIR99021 (6.7 nM). (E) Luciferase analysis was used to determine the CEBPD promoter activity in Rock2-
overexpressing Huh-7 cells treated with CHIR99021 (⁄⁄P < 0.01). (F) EdU cell proliferation assays were performed using Rock2-overexpressing Huh-7 cells treated with
CHIR99021 (⁄⁄⁄P < 0.001, ⁄⁄⁄⁄P < 0.0001). (G) Western blot analysis was performed to determine the expression levels of Rock2, p-GSK3b, total GSK3b, b-catenin and HOXB9 in
Rock2-silenced and Rock2-overexpressing HCC cells. (H) Luciferase analysis for TCF4 transcriptional activity in Rock2-silenced and Rock2-overexpressing HCC cells
(⁄⁄P < 0.01). (I) The effects of Rock2 on the regulation of b-catenin and the transcriptional activity of TCF4 in Rock2-overexpressing Huh-7 cells treated with CHIR99021 were
assessed by Western blotting and luciferase assays (⁄⁄P < 0.01). (J) Western blot analysis showing the levels of Rock2 silencing and b-catenin restoration and their effects on
CEBPD expression in HCCLM3 cells. (K) Luciferase analysis for CEBPD promoter activity (⁄⁄P < 0.01). (L) The overexpression of ectopic b-catenin rescued the cell proliferation
ability of HCCLM3-shRock2 cells (⁄P < 0.05, ⁄⁄P < 0.01). (M) Western blot analysis showing the levels of Rock2 overexpression and b-catenin inhibition and their effects on
CEBPD expression in Huh-7 cells. (N) Luciferase analysis for CEBPD promoter activity (⁄⁄P < 0.01). (O) Downregulation of b-catenin reduced Rock2-enhanced proliferation in
Huh-7 cells. Data were drawn from three independent experiments (⁄⁄P < 0.01).
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Rock2 cells with GSK3 inhibitor CHIR-99021 could markedly inhi-
bit the increase in Gsk-3b phosphorylation and the decrease in
CEBPD expression and activity, meanwhile, the cell proliferation
ability was also decreased (Fig. 4D–F and Fig. S2A–C). These studies
conﬁrmed that Rock2 can regulate CEBPD expression via phospho-
rylation of glycogen synthase kinase 3b (p-GSK3b).
To determine the underlying mechanism through which Rock2
regulates CEBPD by p-GSK3b in HCC cells, we observed the changes
in b-catenin expression regulated by Rock2 through p-GSK3b. The
studies showed that Rock2 can regulate b-catenin expression
through p-GSK3b in neural precursor cells and that b-catenin is
closely associated with the occurrence and development of HCC
[15–17]. Therefore, we investigated whether the regulation of
b-catenin by Rock2 via p-GSK3b also occurs in HCC cells. We
observed that the knockdown of Rock2 decrease b-catenin expres-
sion and the transcriptional activity of TCF4 in HCCLM3 and
SMMC7721 cells, and the b-catenin/TCF4 target gene HOXB9 was
also decreased (Fig. 4G and H). In contrast, the overexpression of
ectopic Rock2 may lead to the reverse effect in Huh-7 and HepG2
cells (Fig. 4G and H). In addition, the effect of Rock2 on the
regulation of b-catenin could be abolished by CHIR-99021
(Fig. 4I and Fig. S2D). These studies conﬁrmed that Rock2 regulates
b-catenin through p-GSK3b in HCC cells.
Finally, to further verify that Rock2 regulates CEBPD expression
through the p-GSK3b/b-catenin pathway in HCC cells, we ﬁrst
overexpressed b-catenin in Rock2-downregulated HCC cells. The
results showed that the overexpression of ectopic b-catenin
inhibited the increases in CEBPD protein expression and promoter
activity, and the cell proliferation ability was also rescued in
Rock2-knockdown HCCLM3 and SMMC7721 cells (Fig. 4J–L and
Fig. S2E–G). We then knocked down b-catenin in Rock2-
overexpressing HCC cells and found that the downregulation of
b-catenin could rescue the decreased CEBPD protein expression
and activity in HepG2- and Huh-7-Rock2 cells (Fig. 4M and N and
Fig. S2H and I). The HCC cell proliferation ability was also
decreased (Fig. 4O and Fig. S2J). The above results conﬁrm that
Rock2 regulates CEBPD-induced HCC proliferation through the
p-GSK3b/b-catenin pathway.
4. Discussion
Rock2 belongs to the serine/threonine protein kinase family.
The studies reported that Rock2 is closely associated with the
occurrence and development of HCC [18]. Our previous research
also revealed that Rock2 overexpression inhibits the ubiquitina-
tion-mediated degradation of MMP2, thereby promoting HCC inva-
sion and metastasis [10]. These reports conﬁrm that Rock2 plays an
important role in the tumorigenesis and progression of HCC.
Recently obtained evidence shows that Rock2 also participates
in the regulation of tumor cell proliferation. Wang et al. showed
that Rock2 can regulate cell division and affect the proliferation
of breast cancer cells through binding to BRCA2 [19]. Our previous
studies also revealed that the reduction of Rock2 can inhibit HCC
cell proliferation via the regulation of Cdc25A [11]. In this study,
we discovered a novel molecular mechanism that underlies the
inhibition of HCC proliferation, which occurs through an increase
in CEBPD expression mediated by Rock2 silencing. First, we found
that the Rock2 mRNA and protein expression levels are high in HCC
tissues and that the CEBPDmRNA and protein expression levels are
low in HCC tissues. The expression levels of Rock2 and CEBPD were
found to be negatively correlated. In addition, we also found that
the knockdown of Rock2 can increase CEBPD expression and
promoter activity and thus inhibit the proliferation of HCC cells
in vitro and in vivo.The previous studies have conﬁrmed that CEBPD is a tumor-
suppressor gene and plays an important role in the inhibition of
tumor cell proliferation. These reports show that CEBPD expression
is downregulated in various tumors, such as breast cancer, cervical
cancer, and neuroblastomas, which and is closely associated with
tumor proliferation and apoptosis [12,14,20,21]. However, the
expression and regulatory mechanisms of CEBPD in HCC remain
unclear. In our study, we ﬁrst conﬁrmed that CEBPD was down-
regulated in HCCs. The silencing of Rock2 can upregulate CEBPD
expression and activity, resulting in decreased cell proliferation
of HCC cells. Moreover, we found that the knockdown of CEBPD
rescued the decreased proliferation ability induced by Rock2
knockdown and that CEBPD upregulation signiﬁcantly decreased
the Rock2-enhanced proliferation. In addition, our studies further
showed that the mechanism underlying the regulation of CEBPD
by Rock2 involves p-GSK-3b/b-catenin signaling.
Previous research have shown that Rock2 can regulate the
expression of downstream genes by binding directly to its
substrate proteins or the p-GSK3b/b-catenin signaling pathway
and thus regulates cell proliferation [16]. However, the detailed
underlying mechanism remains unclear. Our study results showed
no direct interaction of Rock2 and CEBPD proteins in HCC cells.
However, we found that Rock2 can regulate CEBPD through the
p-GSK3b/b-catenin signaling pathway to affect HCC cell prolifera-
tion. This conclusion is based on the following observations. First,
Rock2 can regulate CEBPD through GSK3b phosphorylation in
HCC. Our results showed that the knockdown of Rock2 can signiﬁ-
cantly decrease Gsk-3b phosphorylation and increase CEBPD pro-
tein expression and promoter activity and that cell proliferation
was also decreased. Second, Rock2 can affect b-catenin expression
through the phosphorylation of GSK3b in HCC. The results showed
that the knockdown of Rock2 can decrease both b-catenin expres-
sion and the transcriptional activity of TCF4. Third, we conﬁrmed
that Rock2 can affect CEBPD expression through the p-GSK3b/
b-catenin signaling pathway to regulate HCC cell proliferation.
We found that the knockdown of Rock2 can signiﬁcantly decrease
p-Gsk3b and b-catenin expression and increase CEBPD protein
expression and promoter activity, leading to decreased cell pro-
liferation in HCC cells.
Previous studies have conﬁrmed that the deactivation of
tumor-suppressor genes and the activation of oncogenes are key
steps in tumor formation. The re-activation of tumor-suppressor
gene functions can restore normal phenotypes or inhibit tumor cell
proliferation [22,23]. Our study conﬁrmed that Rock2 silencing can
resume the expression of the tumor suppressor gene CEBPD to inhi-
bit HCC cell proliferation in vitro and in vivo. Furthermore,we found
that Rock2 regulates CEBPD expression through the p-GSK3b/
b-catenin pathway. The newly identiﬁed Rock2-p-GSK3b/b-cate-
nin-CEBPD axis elucidates the proliferation of HCC and represents
a valuable target for HCC therapy.
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